Bina Therapeutics is a research organization that leverages data driven insights to find new treatment strategies for rare conditions.
We use our own technology to expedite qualitative research, enabling rapid consumption of large datasets that formulate a precise knowledgebase of disease pathology, targets, existing research and insights.
Once we have enough data, We shortlist critical targets and carry out molecular docking simulation with high-throughput screening of compounds to identify drugs that exist with greater therapeutic potential than standard of care.
If initial indications from molecular docking simulations combined with internal scientific review form a strong rationale for further exploration, we engage leading experts and institutions specializing in the disease of interest to refine data and advance therapeutic development.
We operate as a “virtually virtual” biotech, treating each disease as a project. We conduct research, preclinical studies often in cell lines of the target disease, and outsource drug manufacturing to our network of GMP-compliant Contract Development and Manufacturing Organizations. This ensures a competitive and efficient approach to drug development, leveraging specialized expertise and cost-effective resources.
Rare diseases often face significant challenges as the cost of research, drug development, and regulatory approval is so high that pharmaceutical companies struggle to recoup their investment in small patient populations.
Drug repurposing offers a promising path to improved patient outcomes, moving beyond a drug’s established interactions to uncover new potential uses. By harnessing computational advancements, we can screen already-approved drugs to identify promising candidates for further investigation. Our pilot project aims to enhance therapeutic strategies for Pseudomyxoma Peritonei.
There are plenty ways to get involved in helping us improve the lives of thousands with rare diseases from sharing our work, contributing to research and fundraising.
We’re in pursuit of a goal that aims to help thousands of people who are suffering from rare diseases starting with Pseudomyxoma Peritonei. Follow our story with frequent updates documenting all of our milestones and outcomes.
